ASCO 2025 – vepdegestrant matches rival degraders
Any hopes of differentiation could come down to side effects.
The month ahead: May’s remaining events
Conference activity picks up, with the big one – ASCO – at the end of the month.
Vepdegestrant’s promise narrows
Arvinas and Pfizer abandon first-line atirmociclib combo plans only disclosed in January.
Pfizer dials down its atirmociclib ambitions
The company is stepping back in second-line breast cancer.
Arvinas’s degrader disappoints
The Pfizer-partnered vepdegestrant shows a benefit in ESR1 mutants, but not in all-comers.
Will Roche's Perseverance pay off?
Giredestrant will soon become the first oral SERD to yield first-line data.
Astra stakes a claim for early camizestrant
But this adds another complexity, and has camizestrant really scored a first-line win?
The month ahead: February’s upcoming events
Approval decisions await Ono and SpringWorks, while key data approach for Pfizer and Arvinas’s SERD.
Arvinas and Pfizer turn away from Ibrance
In first-line breast cancer vepdegestrant will be combined with Pfizer’s investigational CDK4 inhibitor atirmociclib.
SABCS 2024 – Ember-3 dims hopes for Lilly’s SERD
Imlunestrant monotherapy only works in ESR1 mutants, but a Verzenio combo is better in all-comers.
